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Cancer is one of the diseases of greatest concern in developed countries and much effort has been invested in discovering 
and developing therapeutics for curing cancer. Despite the improvements in antineoplastic therapeutics in the last decades, 
cancer is still one of the most harmful diseases worldwide. The global burden of cancer also implies financial costs: these 
can be direct costs, such as those related to treatment, care, and rehabilitation and indirect, which include the loss of 
economic output due to missed work (morbidity costs) and premature death (mortality costs). There are also hidden costs 
such as health insurance premiums and nonmedical expenses that are worth noting. This paper intends to present an 
overview of the generally forgotten impacts that the increasing number of cancer cases can have on the environment, 
workers who handle antineoplastic drugs, and health services. The knowledge available of each of the impacts will be 
addressed and discussed regarding the expected development. Overall, lessons learnt reflect on the impact of cancer 
through aspects not commonly evidenced in the literature or even considered in socio-economic analysis, in part due to 
the fact that these are difficult to contemplate in direct and indirect cancer costs already defined. Attention may be drawn 
to the need of continuous investment in prevention to reduce the negative impact on the environment, and in the health 
of workers who handle antineoplastic drugs for patients’ treatment.
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Globally, cancer is a growing public health problem. It 
is the second cause of death (21 %) after cardiovascular 
diseases (48 %), followed by respiratory diseases (12 %) 
in the sector of non-communicable diseases or diseases 
caused by non-infectious and non-transmissible medical 
conditions (1). Important resources are mobilised in order 
to improve research on new therapeutics, and ultimately 
devise a cure for this particular disease. Despite the increase 
in the effectiveness and specificity of chemotherapeutic 
treatments, cancer still remains one of the most harmful 
diseases (2-4).
In 2012, worldwide incidence of cancer rose to an 
estimated 14 million new cases per year, with an estimated 
8.2 million cancer deaths. The most common cancers 
diagnosed were of lung (1.8 million cases, 13 %), breast 
(1.7 million, 11.9 %) and colon (1.4 million, 9.7 %) (1). 
Some of these numbers can be partially due to environmental 
exposure to carcinogens. In 2003, Boffetta and Nyberg (5) 
stated that despite the relatively small relative risks of 
cancer resulting from exposure to environmental 
carcinogens, the number of cases that might be caused, 
assuming a causal relationship, is relatively large due to the 
high prevalence of exposure. Regarding occupational cancer 
numbers, every year more than 100 000 people die from 
cancer related with exposure occurring in the workplace 
(6-8).
The majority of these cancers are caused by exposure 
to chemical substances. All of these cases could be avoided 
by eliminating the presence of carcinogenic substances in 
workplaces through alternative means of production 
including substitution of chemicals, by a systematic 
implementation of preventative measures and by an 
organisation of work that aims to avoid contact with 
carcinogenic substances (9).
A study conducted by Rushton and colleagues (10) 
intended to estimate the current burden due to past 
occupational exposure for six types of cancers, including 
lung cancer. It was possible to conclude that asbestos 
contributed with over half of the occupational attributable 
deaths, followed by silica, diesel engine exhaust, radon, 
work as a painter, mineral oils in metal workers and in the 
printing industry, environmental tobacco smoke (non-
smokers), work as a welder, and dioxins. Despite asbestos 
being one of the most relevant causal agents for occupational 
lung cancer deaths registered until now, its banning has 
resulted in the reduction of cases only in some countries 
where the use of asbestos was reduced earlier. Most of the 
projections for industrialised countries still suggest that 
asbestos related diseases (including cancer) will continue 
to increase for many years to come (11). Additionally, the 
use of asbestos is increasing in many developing countries 
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and some numbers suggest that exposure may still be high 
in those countries (12). This example demonstrates how 
important it is to eliminate the use of carcinogenic 
substances in all consumers’ products as to avoid their 
presence in workplaces. This should be a common world 
effort and in this way it would be possible to prevent some 
countries, with more fragile economies, having to deal with 
this burden.
Workplace is not the only way of exposure to 
carcinogens: food intake and environmental pollution can 
have an important role as well (13, 14). Given the 
abovementioned, preventing exposure to carcinogens could 
reduce cancer incidence. The global burden of cancer is 
accompanied by a financial load, including direct costs, 
such as treatment and rehabilitation costs, and indirect costs, 
related to productivity losses due to absenteeism, disability, 
and premature death. Hidden costs of cancer also comprise 
health insurance premiums and nonmedical expenses (15, 
16).
Although the exact global financial burden of cancer is 
unknown, in 2011, in the United States of America, the 
estimated direct medical costs for cancer were $88.7 billion 
(15). In 2009, in Europe, cancer costs amounted to €126 
billion, with health care accounting for €51.0 billion (40 %), 
at a €102 cost per person, varying from €184 per person in 
Luxembourg to €16 per person in Bulgaria. Productivity 
losses due to early death cost €42.6 billion and €9.43 billion 
is due to lost working days (17). This research also 
concluded that the highest economic burden was related to 
lung cancer (€18.8 billion, 15 % of overall cancer costs), 
followed by breast cancer (€15.0 billion, 12 %), colorectal 
cancer (€13.1 billion, 10 %), and prostate cancer (€8.43 
billion, 7 %). Moreover, the American Cancer Society (15) 
declares that the global cost of cancer is expected to rise 
due to an increase in the number of new cancer cases, as 
well as in the cost of cancer therapies.  
It is also important to refer to some costs normally 
forgotten, probably due to the difficulty in assigning these 
a number. Examples of these are the impact on the 
environment and in the occupational context, the impact on 
the health of workers who handle antineoplastic drugs. 
Additionally, the need to reorganise health services to 
provide a better treatment of the increasing number of 
cancer patients should be considered. This is essential since, 
nowadays, socio-economic analyses performed in some 
cases to justify the use, and consequently exposure to a 
carcinogenic agent, consider only the costs arising from 
cancer mortality and morbidity, which results, in some 
cases, in an overestimation of the benefits. For instance, in 
the scope of European regulations, the well-known REACH 
(Registration, Evaluation, Authorisation, and Restriction of 
Chemicals) supports a socio-economic analysis, weighing 
up the pros and cons of an action for society as a whole and 
plays a vital role in the restriction and authorisation 
processes for chemicals classified as carcinogenic, 
mutagenic, or toxic to reproduction. Both processes need 
a description of the risks as well as information on the health 
and environmental benefits, the associated costs and other 
socio-economic impacts (18). However, the only costs 
considered are essentially related with cancer mortality and 
morbidity.
Given the abovementioned, this review article aims to 
provide an overview of these generally overlooked impacts 
drawing attention to the costs that should be included in the 
overall decision-making on a carcinogenic agent’s specific 
use (such as industrial chemicals), as well as the real 
scenario of use and exposure versus benefit for the society. 
In that manner, a review of published and grey literature 
was conducted, with incidence on the impact that the 
increasing number of cancer cases can have on the 
environment, workers who handle antineoplastic drugs, and 
in health services. To accomplish this, a thorough search 
was made for papers, other documents, and guidelines 
available in scientific databases and other relevant sources 
related with occupational exposure to antineoplastic drugs 
and also regarding the presence of these drugs in the 
environmental setting.
Antineoplastic drugs in cancer treatment 
Responsible for many advances in therapy during the 
past century, chemicals have a successful history in the 
treatment of illnesses and injuries, and cancer is not an 
exception. Many drugs with diverse modes of action have 
been synthesised and adapted for clinical use. Antineoplastic 
or cytostatic drugs are a heterogeneous group of widely 
used therapeutics for neoplastic and non-neoplastic 
diseases. However, these drugs have been proved to be also 
mutagens, carcinogens, and teratogens (19-25). 
Antineoplastic drugs include alkylating agents (e.g. 
cyclophosphamide, melphalan, chlorambucil, cisplatin), 
antimetabolites (e.g., thioguanine, 5-fluorouracil, 
methotrexate), antibiotics (e.g. doxorubicin), mitotic spindle 
inhibitors (e.g. vincristine), hormones (e.g. diethylstilbestrol), 
free radical generators (e.g. bleomycin) and topoisomerase 
inhibitors (e.g. irinotecan, etoposide) (26-29). There are 
also several so called “new generation” antineoplastic drugs 
that should be taken into account as well, such as taxanes 
(e.g. docetaxel), camptothecin analogues (e.g. irinotecan), 
thymidylate synthase inhibitors (e.g. raltitrexed), nucleoside 
analogues (e.g. gemcitabine), and protein kinase inhibitors 
(e.g., imatinib mesylate) developed for targeted 
chemotherapy (30-32).
In general, chemicals that interact directly with DNA 
by binding covalently or by intercalating, or indirectly by 
interfering with DNA synthesis, were among the first 
chemotherapeutics developed (33). Compounds that inhibit 
the mitotic spindle formation and those that affect the 
endocrine function are also used in cancer chemotherapy 
(34). Also, these drugs can induce reactive oxygen species 
that can lead to DNA damage and mutations, and 
consequently to cell death (35). It has to be pointed out that 
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Given that many of the drugs have similar pharmacology, 
it is possible to consider that they may act additively and/
or synergistically once they enter the environment, possibly 
increasing their overall cytotoxicity, and consequently, the 
risk to aquatic organisms (51-63). Even if the concentration 
of one drug is low, the effect of a mixture might be of 
ecotoxicological importance (39, 64-66).
On this matter, recent studies have revealed that 
mixtures of anticancer drugs in real samples present an 
important toxicological effect when compared with an 
individual drug (67). For instance, a recent research work 
developed by Eleršek and colleagues (50) revealed that a 
low concentration of 5-fluorouracil, imatinib mesylate, and 
etoposide mixture had additive and/or synergistic effects 
on the growth inhibition of green algae and cyanobacteria. 
Also, in mixtures, the same toxic effect as induced by single 
instances of exposure was obtained at much lower 
concentrations of each single compound, meaning that 
lower concentrations in mixtures present the same toxicity 
as a higher single dose (50). Similar effects were observed 
when testing binary mixtures of selected antineoplastic 
drugs also on green algae and cyanobacteria indicating that 
mixtures can have compound-specific and species-specific 
synergistic or antagonistic effects (68). Authors concluded 
that single compound toxicity data are not sufficient to 
predict the aquatic toxicities of such antineoplastic drug 
mixtures. Moreover, in zebrafish liver cells, a mixture of 
cyclophosphamide, 5-fluorouracil, ifosfamide, and cisplatin 
was tested at maximal detected concentrations of each drug 
as determined in the effluents from the oncological ward. 
The tested mixture was not cytotoxic and did not induce 
genomic instability, but it induced a significant increase in 
DNA strand breaks at concentrations of individual 
compounds that were several orders of magnitude lower 
than those that were effective when tested as individual 
compounds. The authors concluded that such mixtures of 
anticancer drugs may pose a threat to aquatic organisms at 
environmentally relevant concentrations and contribute to 
the accumulating evidence that it is not always possible to 
predict adverse effects of complex mixtures based on the 
toxicological data for individual compounds (69).
Although concentrations of antineoplastic drugs in the 
aquatic environment could be below detection limits, they 
can reach alarming levels in biota through bioaccumulation 
and biomagnification processes. Hence, their impact should 
be carefully investigated since unexpected delayed effects 
on the offspring generations could be a matter of concern. 
In that manner, Kovacs and colleagues (70) investigated 
potential threats from low, environmentally relevant, 
concentrations of 5-fluorouracil using a two-generation 
toxicity study design with zebrafish (Danio rerio). Exposure 
of zebrafish to a selected antineoplastic drug was initiated 
with adult F0 generation and continued through the 
hatchings and adults of the F1 generation, and the hatchings 
of the F2 generation. Results indicated that even exposure 
to low concentrations of antineoplastic drugs might affect 
these drugs are often used in combination, in order to 
achieve additive and/or synergistic effects on tumour cells 
resulting from their differing modes of action. However, 
most, if not all, of these chemical agents are generally non-
selective and along with tumour cells, normal cells may 
undergo cyto/genotoxic damage (26, 36-39). 
The in vivo exposure to antineoplastic drugs has been 
shown to induce different types of lesions in DNA, 
according to the inherent mechanism of action and also 
depending on the particular stage of cell cycle at the time 
of treatment. The majority of lesions occur during DNA 
synthesis, often due to misreplication. Both neoplastic and 
normal cells attempt to repair them. However, if unrepaired, 
DNA lesions may give rise to chromosome aberrations, 
which are able to interfere with the transcription and 
replication of DNA, resulting in cytotoxic and mutagenic 
effects. Due to all these characteristics, growing evidence 
suggests that secondary neoplasms may arise as a 
consequence of chemotherapy (37, 40-43).
Antineoplastic drugs impact on the environment 
Cancer incidence has increased in the so-called “modern 
societies” in the last years, and so has the use of 
antineoplastic drugs (2). Because of this, the amount of 
such drugs, their metabolites and transformation products 
in the environment is of great concern since they may induce 
adverse effects on both the environment and human health. 
A particular emphasis has been put on the impact on the 
aquatic environment (24, 44-52). 
Antineoplastic drugs commonly used in chemotherapy 
treatment enter wastewater trough sewage treatment plants 
and through excretion of the non-metabolised drug 
following its administration to patients. However, despite 
the increasing number of cancer patients, these drugs have 
received minor attention, considering their high 
pharmacological potency, foetotoxic, genotoxic, and 
teratogenic properties, which may well induce genetic and 
cell cycle alterations in aquatic fauna and flora if there is 
chronic exposure (51, 53, 54). The concern with these 
substances derives from their presence in freshwater 
systems and the consequent contamination of the potable 
water supply, with risk of human exposure (51, 54). Some 
authors state that, due to the continual input into the aquatic 
compartment, these drugs should be considered “pseudo”-
persistent pollutants (50, 55, 56).
Some of these drugs are not completely metabolised 
and are poorly biodegradable. They can also be resistant to 
conventional biological and chemical processes used during 
wastewater treatment (53) and may represent a challenge 
for the state-of-the-art technologies of water decontamination 
(2, 48). Due to higher analytical sensibility to antineoplastic 
drugs, some of these chemicals have been reported in 
hospital waste effluents, in sewage treatment plants, and 
river water. A growing interest in this topic has been verified 
and data have been published in several studies (57-62).
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fish populations over long-term exposure of several 
generations, which suggests that further studies into multi-
generation toxicity are warranted.
Additionally, some studies state that there is still a lack 
of research on antineoplastic agents, their metabolites and 
transformation products, as well as on environmental fate 
and impact (2, 51). A fraction of these drugs is metabolised 
before being excreted and future studies should focus on 
the screening of metabolites and transformation products 
(which could also be present in wastewaters) since most of 
these compounds can have equal or even greater activity 
than the parent compounds (2, 71, 72).
Finally, it is important to bear in mind that the problem 
is not only focused in hospitals’ wastewater as these drugs 
are also administered in outpatient clinics. Therefore, the 
release of antineoplastic drugs is very diffuse in the 
environment and difficult to control (51). Besides 
addressing solutions to treat hospital effluent “on-site” 
(before being discharged into the urban sewage collection 
system), management of human excretions (urine and 
faeces) from oncologic patients as a separate form of waste 
with potential environmental impact needs to be studied. 
Antineoplastic agents must be considered a group of new 
and emerging environmental pollutants, which can produce 
impact on aquatic life, wastewater treatment plants and 
water receiving effluents and in that manner, more data on 
the occurrence and effects of such pollutants are needed to 
enable efficient environmental risk assessment (2, 73).
Occupational exposure to antineoplastic drugs 
According to the European Guidelines (74), any use of 
carcinogenic, mutagenic or teratogenic substances, 
including the application in health care settings, is assigned 
to the highest risk level (20-23, 75). Based on epidemiological 
reports, animal carcinogenicity data, and the outcomes of 
in vitro genotoxicity studies, several antineoplastic drugs 
have been classified by the International Agency for 
Research on Cancer (IARC) as belonging to the group of 
human carcinogens (Group 1), probable human carcinogens 
(Group 2A), or possible human carcinogens (Group 2B) 
(76, 77). 
Many anticancer agents have the potential to cause 
genetic alterations, which may lead to the development of 
cancer if they interact with proto-oncogenes or tumour 
suppressor genes, which are involved in controlling cell 
growth or differentiation (78). Exposure to any genotoxic 
agents may initiate a sequence of events that leads to adverse 
health effects. Although the potential therapeutic benefits 
of hazardous drugs outweigh the risks of side effects for ill 
patients, exposed health care workers risk these same side 
effects with no therapeutic benefit. 
Along with the increasing number of cancer patients, a 
higher number of workers are potentially needed to handle 
production and administration tasks relative to antineoplastic 
drugs. In Portugal, for instance, since 2007 there has been 
no substantial recruitment of pharmacy professionals in 
order to follow the number of patients who need 
chemotherapy care. Also, the centralisation of cytotoxic 
production reduced it to five public health institutions, and 
the increased demand for these drugs forced teams to work 
in shifts (79), with relocation of professionals from other 
sectors of the hospital pharmacy to the cytotoxic oncology 
area. 
Workers may be exposed to a drug at different stages 
of its life cycle – from manufacture to transport and 
distribution, during its use in health care or home care 
settings, or at its final waste disposal. Health care workers 
who prepare or administer hazardous drugs or who work 
in areas where they are used may be exposed to these agents 
in the air, on work surfaces, contaminated clothing, medical 
equipment, patient excreta, and other surfaces (80-83). 
These workers include shipping and receiving personnel, 
pharmacists and pharmacy technicians, nursing personnel, 
and environmental services personnel (20). Workers 
employed in the synthesis and production of these products 
and staff involved in cleaning, transport, and disposal of 
hazardous drugs or contaminated material may all face 
health risks (20, 36, 84-86). A study done by Meijster and 
colleagues (84) discussed the most important occupational 
settings outside hospitals in the Netherlands, where 
exposure to antineoplastic can also occur. Settings such as 
home care, nursing homes, and laundry facilities are the 
ones identified with higher exposure and are all related with 
probable care of cancer patients.
The biological effects may vary depending on the 
drug(s), its dose, and individual genetic susceptibility (80), 
but it is difficult to assess how much drug is absorbed in 
the course of handling agents at the workplace. The main 
focus of concern has dwelled upon the pharmacy and 
nursing personnel who mix and administer drugs and who 
are likely to experience the highest exposure intensity (87). 
Inhalation and skin contact/absorption are the most likely 
routes of exposure, but unintentional ingestion from hand 
to mouth contact and unintentional exposure from a needle 
is also possible (80, 82, 83, 88, 89). Inhalation results from 
aerosolisation of powder or liquid during reconstitution and 
spillage taking place while preparing or administering to 
patients; skin contact or skin absorption results from contact 
with contaminated surfaces mostly when control measures 
are inadequate. This type of exposure seems to have the 
most important role in dermal absorption (20, 79, 90, 91). 
Contaminated food or cigarettes, but also hand contact 
with contaminated equipment used in preparing and 
administering these drugs, can lead to oral ingestion. 
Furthermore, patients may excrete these drugs and their 
metabolic by-products in body wastes, exposing personnel 
who handle such items (80, 89). Contamination of 
workplace surfaces and permeation of gloves to some 
antineoplastic drugs were reported already in several studies 
(22, 79, 80, 92). 
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The National Institute for Occupational Safety and 
Health (NIOSH) in the USA has compiled several case 
studies that suggest both acute and long-term health effects 
associated with antineoplastic drug occupational exposure 
scenarios. Various studies have associated workplace 
exposure with health effects such as skin rashes, hair loss, 
irritation, hypersensitivity, and headaches after reported 
skin contact (28, 93-96). Negative reproductive health 
outcomes are also associated with antineoplastic exposure 
(93, 97, 98). Spontaneous abortions have been reported 
approximately twice more often among exposed pregnancies 
than unexposed ones (94); the same goes for congenital 
malformations, infertility, and possibly leukaemia, as well 
as other cancers (80, 94, 99). 
Health care workers handling antineoplastic drugs 
usually implement collective and individual protective 
measures. However, contamination of the work environment 
is still possible and the safety measures employed can be 
insufficient to prevent exposure (9, 100, 101). Even when 
strict protocols and standard operating procedures have 
been applied, studies reported the presence of widespread 
surface contamination (79, 102).
In a hospital setting, exposure to several antineoplastic 
drugs occurs simultaneously. The effects of such mixtures, 
at cell level and on human health in general, are unpredictable 
and unique due to the differences in the practice of hospital 
oncology departments, in the number of patients, protection 
devices available, and the experience and safety procedures 
of health professionals that handle these drugs (39, 66, 80, 
103, 104). The growing use of complex mixtures of known 
and new antineoplastic drugs in cancer treatment emphasises 
concerns about occupational exposure and genotoxic risks 
of workers handling such mixtures. The presence of drugs 
in different amounts and with different mechanisms of 
action suggests the need to study the relationship between 
the presence of genotoxic components in the mixture and 
the ensuing effects, taking into account the mechanism of 
action of each component per se (39, 66, 105).
Presently, the concern also includes long-term risks of 
handling monoclonal antibodies (MABs), which were 
introduced into clinical practice in the mid-1980s, with their 
use in the healthcare setting increasing over the past decade. 
MABs have become established in the treatment of a variety 
of disease states including cancer, rheumatoid arthritis, 
transplanted organ rejection, psoriasis, and asthma. This 
group is more selective for cancer cells, and manufacturers 
have minimal data on the possible long term risks of 
handling MABs predominantly because they are not 
required to provide this information for licensing purposes 
(106-108).
Evolution of cancer care units
As already mentioned, several studies have been 
conducted to assess the financial burden of cancer. One the 
one hand, the financial burden of cancer, despite being high, 
is comparable or lower in comparison with that of other 
chronic diseases; for example, the burden of mental health 
and circulatory system is higher than that of cancer (109, 
110). On the other hand, however, the burden of cancer has 
been increasing over the recent years, related to the 
increasing incidence, survival, and life expectancy of 
survivors, as well as the emergence of new therapies with 
extremely high costs (111).
All these studies on the cancer financial burden have 
appraised direct costs, which mainly consist of the costs of 
cancer treatments, and several studies have also evaluated 
indirect costs, mainly represented by productivity losses 
due to treatments, morbidity, and premature death. Yet, the 
increasing use of chemotherapy has prompted hospitals to 
reorganise their services in order to adapt to the most up-
to-date way of providing cancer care. This reorganisation 
started in the 1990s and has been on-going since then, driven 
by the will to adapt services to new patient management 
procedures. We consider that this regular need for 
reorganisation represents an additional burden of cancer, 
which has rarely been addressed in the literature.
We briefly discuss here the shift from inpatient to 
outpatient care and the implementation of multi-disciplinary 
teams. Guidelines published in 1996 clearly mentioned the 
shift in the administration of chemotherapy from 
hospitalisation towards outpatient settings, which may be 
the hospital outpatient facilities or the oncologist’s office 
(112). The advantages of care delivery as outpatient are 
listed in these guidelines, mainly referring to the easier way 
of administering drugs; the patient preferences (outpatient 
care provides more comfort and psychological well-being 
than inpatient settings); lower and better monitoring of 
costs; and greater flexibility of schedules. This shift towards 
outpatient settings was also driven by the pressure from 
hospital administrations and third-party payers to reduce 
expenditures and to free inpatient beds for competing needs 
(113). In practice, treatment is provided by skilled nurses 
over a few hours, using central venous access catheters, 
under the supervision of an oncologist immediately 
available to answer questions, revise medications, or 
intervene in case of a problem (112). 
Outpatient therapy is now common for solid tumours 
but has also been adopted more recently for other more 
complex treatments; for example, high-dose chemotherapy 
followed by autologous hematopoietic stem cell 
transplantation (HSCT), and in the allogeneic non-
myeloablative HSCT (113). In addition to previous 
arguments, the use of outpatient settings was also driven in 
this case by the long waiting time for inpatient care leading 
to delays in treatment. Savoie and colleagues (113) 
demonstrated that outpatient care was safe and feasible for 
these more aggressive treatments. These results confirm the 
findings of earlier studies, which showed that outpatient 
high-dose chemotherapy and autologous stem cell 
transplantation are efficient, effective, and acceptable (114, 
115). More recently even, the challenge of shifting towards 
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outpatient care has been raised for other cancers, also with 
favourable outcomes: the treatment by vincristine, 
dactinomycin, and cyclophosphamide for children with 
solid tumours, as outpatient instead of the traditional two-
day inpatient stay, has proven safe, cheaper, and more 
satisfactory for the patient (116); outpatient delivery of 
chemotherapy for acute lymphoblastic leukaemia/
lymphoma was safe and not associated with increased 
toxicity as compared to inpatient delivery (117); outpatient 
management after chemotherapy for adults with acute 
myeloid leukaemia or myelodysplastic syndrome reduced 
costs and use of IV antibiotics (118). In other terms, the 
administration of chemotherapy in outpatient settings 
produces comparable outcomes while increasing patients’ 
satisfaction and reducing costs.
However, this evolution in the management of 
chemotherapy raises serious challenges, which require 
additional precautions and higher expenditures. In 
particular, as compared to inpatient delivery, outpatient 
chemotherapy is performed over a shorter period of time, 
with a higher volume of interventions, and a lower level of 
control. The risks are higher if one considers lower 
continuity, self-administration of medications, and 
occurrence of side effects at home; a 3 % rate of medical 
errors was measured in a study. As the authors mention, the 
higher risk of error needs to be counteracted by commitment 
to error reduction and a culture of safety, including a 
computerised clinical decision support system, which is 
used at the different stages of care pathways by a multi-
disciplinary team (119).
In the meantime, cancer therapies have rapidly 
become more efficacious and diverse but with an 
increasing complexity for professionals to select the 
optimal management plan. As mentioned by Fleissig and 
colleagues (120), there is thus a higher need for coordination 
and communication between health professionals and 
patients, which a multi-disciplinary team (MDT) can fulfil. 
The MDTs have various expected benefits, which Fleissig 
and colleagues (120) have detailed: better coordination of 
care (permitting more consistent information to patients 
and more efficient and simplified processes); greater 
continuity of care; better communication between 
professionals and with patients; better clinical outcomes 
(mostly because teams involving various skills and 
knowledge are more likely to opt for the most adequate 
management plan); and higher satisfaction and well-being 
of patients and health professionals (essentially because of 
the supportive environment).
Similarly to the shift towards outpatient care, the 
implementation of MDTs is challenging and requires 
commitment, support, and funding. The adequate 
functioning of MDTs requires leadership, administrative 
dedicated support to ensure the coordination, time and 
conditions for regular meetings, and larger well-financed 
teams (120). These requirements may be difficult to fulfil 
under adverse circumstances, such as budget pressure, 
hierarchical boundaries, insufficient staff, or historical and 
cultural barriers between health professions and services.
New cancer therapies have dramatically improved 
clinical outcomes; the efficacy and efficiency of cancer 
management, however, are likely to be enhanced under 
adequate and innovative organisation of cancer care units, 
involving in particular outpatient delivery and MTDs. These 
new forms of managing cancer care are, however, 
potentially difficult to implement and a strong commitment 
and additional funding are required. These are part of the 
hidden costs of cancer care, although these costs are very 
likely to be compensated in the long run by efficiency gains. 
CONCLUSION 
This paper reflects on the impact of cancer through 
aspects not commonly evidenced in the literature or even 
considered in socio-economic analysis, in part due to the 
fact that these are difficult to contemplate in direct and 
indirect cancer costs already defined. Three important 
impacts resulting from cancer are presented: antineoplastic 
relationship with the environment, the health of workers, 
and new organisation of health facilities. Considering this, 
attention may be drawn to the need of continuous investment 
in prevention, search for alternatives to substitute 
carcinogenic agents in industrial uses, thus reducing the 
negative impact on the environment, and in the health of 
workers who handle antineoplastic drugs for patients’ 
treatment. Additionally, cancer prevention investment will 
allow health care units to better address patients’ needs, 
focusing on diseases where prevention has a limited or null 
impact.
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Zaboravljeni učinci raka na javno zdravstvo – pregled
Rak je jedan od najvećih problema javnog zdravstva diljem svijeta. To je jedna od najproblematičnijih bolesti u razvijenim 
zemljama te je dosta napora uloženo u otkrivanje i razvoj lijekova za liječenje raka. Unatoč razvoju antineoplastičnih 
lijekova u proteklim desetljećima, rak je i dalje jedna od najštetnijih bolesti na globalnoj razini. Globalno opterećenje 
raka uključuje i financijske troškove: može se raditi o izravnim troškovima poput onih vezanih uz liječenje, njegu i 
rehabilitaciju te o neizravnima, koji uključuju gubitak ekonomskih rezultata zbog izostanka s posla (troškovi morbiditeta) 
i prerane smrti (troškovi smrti). Tu su i skriveni troškovi poput premija zdravstvenog osiguranja i nemedicinskih troškova, 
koje isto tako valja istaknuti. U radu je dan pregled općenito zaboravljenih učinaka rastućeg broja slučajeva oboljenja od 
raka na okoliš, na zaposlenike koji rukuju antineoplastičnim lijekovima i na zdravstvene službe. Velika je pozornost 
posvećena postojećemu znanju o svakom pojedinačnom utjecaju te je razrađen očekivani razvoj navedenih učinaka. 
Općenito, prikazan je utjecaj raka kroz aspekte koji se uobičajeno ne dokumentiraju u literaturi niti razmatraju u 
socioekonomskim analizama, a djelomično je razlog tomu što ih je teško razmotriti unutar već definiranih izravnih i 
neizravnih troškova. Pozornost valja posvetiti i potrebi trajnoga ulaganja u prevenciju kako bi se smanjio negativan učinak 
na okoliš i na zaposlenike koji rukuju antineoplastičnim lijekovima.
KLJUČNE RIJEČI: globalno opterećenje; troškovi raka; zdravlje na radu
Viegas S et al. Forgotten public health impacts of cancer - an overview 
Arh Hig Rada Toksikol 2017;68:287-297
110. Heijink R, Noethen M, Renaud T, Koopmanschap M, Polder 
J. Cost of illness: an international comparison. Australia, 
Canada, France, Germany and The Netherlands. Health 
Policy 2008;88:49-61. doi: 10.1016/j.healthpol.2008.02.012
111. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. 
Projections of the cost of cancer care in the United States: 
2010-2020. J Natl Cancer Inst 2011;103:117-28. doi: 
10.1093/jnci/djq495
112. Dollinger M. Guidelines for hospitalization for chemotherapy. 
Oncologist 1996;1:107-11. PMID: 10387975
113. Savoie ML, Nevil TJ, Song KW, Forrest DL, Hogge DE, 
Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze 
CL, Lavoie JC. Shifting to outpatient management of acute 
myeloid leukemia: a prospective experience. Ann Oncol 
2006;17:763-8. doi: 10.1093/annonc/mdl011
114. Summers N, Dawe U, Stewart DA. A comparison of inpatient 
and outpatient ASCT. Bone Marrow Transplant 2000;26:389-
95. doi: 10.1038/sj.bmt.1702534
115. Glück S, des Rochers C, Cano C, Dorreen M, Germond C, 
Gill K, Lopez P, Sinoff C. High-dose chemotherapy followed 
by autologous blood cell transplantation: a safe and effective 
outpatient approach. Bone Marrow Transplant 1997;20:431-
4. doi: 10.1038/sj.bmt.1700901
116. Beaty RS, Bernhardt MB, Berger AH, Hesselgrave JE, 
Russell HV, Okcu MF. Inpatient versus outpatient vincristine, 
dactinomycin, and cyclophosphamide for pediatric cancers: 
Quality and cost implications. Pediatr Blood Cancer 
2015;62:1925-8. doi: 10.1002/pbc.25610
117. Abro EU, Morris K, Hodges G, Butler JP, Curley C, Pillai 
ES, Kennedy GA. Outpatient administration of Hyper-CVAD 
chemotherapy for acute lymphoblastic leukaemia / lymphoma 
is safe and associated with similar toxicity compared to 
inpatient delivery. Blood 2013;122:5017.
118. Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, 
Hendrie PC, Becker PS, Pottinger PS, Estey EH, Walter RB. 
Resource utilization and safety of outpatient management 
following intensive induction or salvage chemotherapy for 
acute myeloid leukemia or myelodysplastic syndrome: 
nonrandomized clinical comparative analysis. JAMA Oncol 
2015;1:1120-7. doi: 10.1001/jamaoncol.2015.2969
119. Gandhi TK, Bartel SB, Shulman LN, Verrier D, Burdick E, 
Cleary A, Rothschild JM, Leape LL, Bates DW. Medication 
safety in the ambulatory chemotherapy setting. Cancer 
2005;104:2477-83. doi: 10.1002/cncr.21442
120. Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary 
teams in cancer care: are they effective in the UK? Lancet 
Oncol 2006;7:935-43. doi: 10.1016/S1470-2045(06)70940-8
